Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports
WSBF Waterstone Financial Inc

Health Care : Biotechnology | Small Cap Value
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

8:30 am ET May 19, 2020 (Globe Newswire) Print

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that researchers at the University of Paris have utilized mass cytometry to identify profound changes in the immune systems of critically ill COVID-19 patients. The findings may help define a population of COVID-19 patients at high risk for becoming critically ill, and they suggest a possible benefit from anti-inflammatory therapies.

The study, available online through medRxiv and pending peer review, utilized the Fluidigm MaxparDirect(TM) Immune Profiling Assay(TM) and Maxpar Pathsetter(TM) analysis software. The assay offers a fixed panel of 30 standard markers of immune activity, to which the researchers added two exploratory markers. Analyses of multiple markers revealed changes in the populations of different types of immune cells, and most important, to their antiviral response in 50 patients with varying disease severity.

"The immunological features and molecular mechanisms involved in COVID-19 are as yet not well-understood, and we urgently need a deeper understanding across the different stages of the disease," said Dr. Benjamin Terrier, MD, PhD, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Public Assistance Hospitals of Paris-Center, University of Paris. "A means to identify groups at high risk for severe COVID-19 could provide valuable insights into effective approaches to treatment."

All patients were tested 8 to 12 days following the onset of symptoms and in the absence of anti-inflammatory therapy. In-depth profiling of immune cell populations and their respective functions using mass cytometry, gene expression studies and evaluation of the levels of proteins secreted by the cells found that profound impairment of type I interferon (IFN) activity was unique to critically ill patients. This suggests that type I IFN deficiency is a hallmark of severe COVID-19 and that these patients could benefit from anti-inflammatory therapies targeting IL-6 or TNF-a inflammatory cytokines.

"A rapidly emerging body of data demonstrates the value of mass cytometry and our Maxpar Direct Immune Profiling Assay in studies that provide critical and potentially actionable insights for approaches to COVID-19 therapy," said Chris Linthwaite, President and CEO of Fluidigm. "Accurate and meaningful assessments of diverse biomarkers that have diagnostic, prognostic or therapeutic value are essential in addressing the unique and urgent challenges of this global health crisis.

"Speed is equally critical," Linthwaite said. "The team at University of Paris, using our standardized, pre-designed and optimized kit, was able to go from experiment conception to pre-print publication in 25 days. We are committed to supporting researchers around the globe with tools and technologies to effectively respond to the global pandemic, both in state-of-the-art immune profiling of patients and in virus detection in populations."

The online archive medRxiv was founded by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution, Yale University, and BMJ, a global health care knowledge provider. It provides a platform for researchers to share their work and comment and receive feedback on it prior to journal publication.

About Fluidigm

Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit

Fluidigm, the Fluidigm logo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements for Fluidigm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential value of and demand for Fluidigm's mass cytometry technology and products for COVID-19-related applications. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm's Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Available Information

We use our website (, investor site (, corporate Twitter account (@fluidigm), Facebook page (, and LinkedIn page ( as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.



Mark Spearman

Senior Director, Corporate Communications

650 243 6621


Agnes Lee

Vice President, Investor Relations

650 416 7423

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.